LU91306I2 - Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN) - Google Patents

Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)

Info

Publication number
LU91306I2
LU91306I2 LU91306C LU91306C LU91306I2 LU 91306 I2 LU91306 I2 LU 91306I2 LU 91306 C LU91306 C LU 91306C LU 91306 C LU91306 C LU 91306C LU 91306 I2 LU91306 I2 LU 91306I2
Authority
LU
Luxembourg
Prior art keywords
yarvitan
mitratapide
optionally
pharmaceutically acceptable
acid addition
Prior art date
Application number
LU91306C
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/455,304 external-priority patent/US5521186A/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of LU91306I2 publication Critical patent/LU91306I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LU91306C 1994-10-27 2007-01-17 Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN) LU91306I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP94203120 1994-10-27
US08/455,304 US5521186A (en) 1994-10-27 1995-05-31 Apolipoprotein-β synthesis inhibitors
PCT/EP1995/004111 WO1996013499A1 (fr) 1994-10-27 1995-10-19 Inhibiteurs de synthese d'apolipoproteines-b

Publications (1)

Publication Number Publication Date
LU91306I2 true LU91306I2 (fr) 2007-03-19

Family

ID=26136684

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91306C LU91306I2 (fr) 1994-10-27 2007-01-17 Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)

Country Status (30)

Country Link
US (1) US5929075A (fr)
EP (1) EP0788496B1 (fr)
JP (1) JP3025907B2 (fr)
KR (1) KR100227231B1 (fr)
CN (1) CN1068000C (fr)
AP (1) AP779A (fr)
AT (1) ATE198889T1 (fr)
AU (1) AU697744C (fr)
BG (1) BG63694B1 (fr)
BR (1) BR9509436A (fr)
CA (1) CA2203274C (fr)
CY (1) CY2256B1 (fr)
CZ (1) CZ286476B6 (fr)
DE (3) DE69519995T2 (fr)
DK (1) DK0788496T3 (fr)
ES (1) ES2155535T3 (fr)
FI (1) FI119548B (fr)
GR (1) GR3035519T3 (fr)
HR (1) HRP950532B1 (fr)
HU (1) HU219862B (fr)
IL (1) IL115771A (fr)
LU (1) LU91306I2 (fr)
NO (1) NO311937B1 (fr)
NZ (1) NZ295353A (fr)
OA (1) OA10479A (fr)
PT (1) PT788496E (fr)
RO (1) RO118715B1 (fr)
SK (1) SK281908B6 (fr)
TR (1) TR199501295A2 (fr)
WO (1) WO1996013499A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL340305A1 (en) * 1997-11-03 2001-01-29 Janssen Pharmaceutica Nv Composition of agents reducing the level of lipoides
CN1308523A (zh) * 1998-04-27 2001-08-15 詹森药业有限公司 含有用降脂剂和聚合物包衣的丸芯的微丸
ES2195653T3 (es) 1998-12-22 2003-12-01 Janssen Pharmaceutica Nv Compuesto de s-oxido que disminuyen los lipidos.
DE19945982A1 (de) * 1999-09-24 2001-03-29 Knoll Ag Geschwindigkeitsbestimmte Partikel
US20050132022A1 (en) * 2003-12-12 2005-06-16 International Business Machines Corporation Computer system with LAN-based I/O
WO2005070390A2 (fr) * 2004-01-21 2005-08-04 Janssen Pharmaceutica N.V. Solution orale de mitratapide
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
US20080280922A1 (en) * 2004-04-09 2008-11-13 Marc Alois Celine Maria Engelen Intermittent Dosing Regimen For Overweight and Obese Subjects
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
EP1890767A2 (fr) * 2005-05-27 2008-02-27 Pfizer Products Inc. Combinaison d'un antagoniste des recepteurs cannabinoides-1 et d'un inhibiteur des proteines microsomales de transfert de triglycerides pour traiter l'obesite ou maintenir une perte de poids
EP1912968A1 (fr) * 2005-08-04 2008-04-23 Pfizer Limited Composes piperidinoyl-pyrrolidine et piperidinoyl-piperidine
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CA2642922C (fr) * 2006-02-23 2011-08-02 Pfizer Limited Piperidinoylpyrrolidines en tant qu'agonistes du recepteur de la melanocortine de type 4
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
JP2010509392A (ja) 2006-11-13 2010-03-25 ファイザー・プロダクツ・インク ジアリール、ジピリジニルおよびアリール−ピリジニル誘導体ならびにその使用
US8404896B2 (en) 2006-12-01 2013-03-26 Bristol-Myers Squibb Company N-((3-benzyl)-2,2-(bis-phenyl)-propan-1-amine derivatives as CETP inhibitors for the treatment of atherosclerosis and cardiovascular diseases
JP5350367B2 (ja) * 2007-05-25 2013-11-27 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （２ｓ−シス）−２−（ブロモメチル）−２−（４−クロロフェニル）−１，３−ジオキソラン−４−メタノールメタンスルホネート（エステル）の改良された合成
US8592403B2 (en) * 2008-08-06 2013-11-26 Pfizer Limited Diazepine and diazocane compounds as MC4 agonists
CN102906087B (zh) * 2010-05-19 2016-03-23 桑多斯股份公司 制备手性三唑酮的方法
TWI903299B (zh) 2018-03-08 2025-11-01 美商英塞特公司 作為PI3K-γ抑制劑之胺基吡嗪二醇化合物
WO2020010003A1 (fr) 2018-07-02 2020-01-09 Incyte Corporation DÉRIVÉS D'AMINOPYRAZINE UTILISÉS EN TANT QU'INHIBITEURS DE PI3K-γ

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4313953A (en) * 1978-06-23 1982-02-02 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4267179A (en) * 1978-06-23 1981-05-12 Janssen Pharmaceutica, N.V. Heterocyclic derivatives of (4-phenylpiperazin-1-yl-aryloxymethyl-1,3-dioxolan-2-yl)methyl-1H-imidazoles and 1H-1,2,4-triazoles
US4766125A (en) * 1981-06-23 1988-08-23 Janssen Pharmaceutica N.V. N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4619931A (en) * 1983-02-28 1986-10-28 Janssen Pharmaceutica, N.V. [[4-[4-(4-phenyl-1-piperazinyl)phenoxymethyl]-1,3-dioxolan-2-yl]methyl]-1H-imidazoles and 1H-1,2,4-triazoles
CA1292472C (fr) * 1985-12-03 1991-11-26 Alfonsus Guilielmus Knaeps Derives des ({4-¬4-(4-phenyl-1-piperazinyl)-phenoxymethyl|- 1,3-dioxolan-2-yl}methyl)-1h-imidazoles et 1h-1,2,4-triazoles
NZ223799A (en) * 1987-03-25 1989-12-21 Janssen Pharmaceutica Nv Azolylmethyl-dioxolanylmethoxyphenyl-piperazinyl-phenyl-triazolones and antimicrobial compositions
CA1331757C (fr) * 1988-02-29 1994-08-30 Janssen Pharmaceutica Naamloze Vennootschap 5-lipoxygenase inhibant les 4-(4-phenyl-1-piperazinyl)phenols
WO1994020063A2 (fr) * 1993-03-04 1994-09-15 Cytoven International N.V. Tryptophane pharmaceutique contenant des compositions dipeptidiques et modes d'utilisation
US5521186A (en) * 1994-10-27 1996-05-28 Janssen Pharmaceutica N.V. Apolipoprotein-β synthesis inhibitors

Also Published As

Publication number Publication date
FI119548B (fi) 2008-12-31
SK50797A3 (en) 1998-04-08
DK0788496T3 (da) 2001-06-18
CY2256B1 (en) 2003-07-04
DE122007000005I2 (de) 2008-04-24
WO1996013499A1 (fr) 1996-05-09
JPH09511759A (ja) 1997-11-25
US5929075A (en) 1999-07-27
DE69519995D1 (en) 2001-03-01
HRP950532A2 (en) 1997-08-31
CA2203274A1 (fr) 1996-05-09
FI971784L (fi) 1997-04-25
HRP950532B1 (en) 2001-06-30
AU3868095A (en) 1996-05-23
AU697744C (en) 2002-08-22
DE69519995T2 (de) 2001-08-23
CN1068000C (zh) 2001-07-04
KR100227231B1 (ko) 1999-11-01
CZ119897A3 (cs) 1998-03-18
ATE198889T1 (de) 2001-02-15
NO971895D0 (no) 1997-04-24
BR9509436A (pt) 1998-01-06
GR3035519T3 (en) 2001-06-29
NO311937B1 (no) 2002-02-18
RO118715B1 (ro) 2003-09-30
NO971895L (no) 1997-04-24
DE122007000005I1 (de) 2007-04-26
HU219862B (hu) 2001-08-28
AU697744B2 (en) 1998-10-15
FI971784A0 (fi) 1997-04-25
ES2155535T3 (es) 2001-05-16
EP0788496B1 (fr) 2001-01-24
AP779A (en) 1999-11-03
TR199501295A2 (tr) 1996-06-21
IL115771A (en) 2000-02-29
EP0788496A1 (fr) 1997-08-13
SK281908B6 (sk) 2001-09-11
NZ295353A (en) 1998-08-26
CA2203274C (fr) 2002-02-19
OA10479A (en) 2002-04-09
BG101402A (en) 1997-10-31
MX9703074A (es) 1997-07-31
IL115771A0 (en) 1996-01-19
JP3025907B2 (ja) 2000-03-27
CZ286476B6 (en) 2000-04-12
AP9700968A0 (en) 1997-04-30
PT788496E (pt) 2001-07-31
CN1161695A (zh) 1997-10-08
HUT77360A (hu) 1998-03-30
BG63694B1 (bg) 2002-09-30

Similar Documents

Publication Publication Date Title
LU91306I2 (fr) Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN)
LU88809I2 (fr) Lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable
LU91442I2 (fr) "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate"
LU91372I2 (fr) Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo)
LU88746I2 (fr) Valaciclovir facultativement sous la forme d'un sel pharmaceutiquement acceptable y compris le sel d'addition de l'acide chlorhydrique
LU91290I2 (fr) Céfovécine, optionnellement sous la forme d'un sel, dont le sel de sodium (CONVENIAr)
LU90593I2 (fr) Quetiapine facutativement sous forme d'un sel pharmaceutiquement acceptabe
LU92428I2 (fr) Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable
LU92407I2 (fr) Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate
LU88842I2 (fr) Nebivolol optionnellement sous forme d'un sel ou d'un hydrate pharmaceutiquement acceptable en particulier hydroclorure de Nebivolol
LU90426I2 (fr) Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir
LU91599I2 (fr) Lasofoxifene, optionnellement sous forme d'un sel d'addition acide, d'un N-oxyde, d'unester ou d'un sel d'ammonium quaternaire, non toxiques et pharmacologiquement acceptables, y compris le sel tartrate (FABLYN - lasofoxifene)
LU90468I2 (fr) Zanamivir facultativement sous la forme d'un sel ou d'un derive pharmaceutiquement acceptable
LU91181I2 (fr) Ziconotide, optionnellement sous forme d'un sel avec un acide pharmaceutiquement acceptable, y compris acetate de ziconotide (prialt).
LU92699I2 (fr) Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués
LU90234I2 (fr) Une combination comprenant de la lamivudine facultativement sous la forme d'un sel pharmaceutiquement acceptable et de la zidovudine
NO2010003I1 (no) Prukaloprid eller et farmasøytisk aksepterbart syreaddisjonssalt derav
LU92397I2 (fr) Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
FI925342L (fi) Menetelmä terapeuttisesti aktiivisen (+)- -(2,3-dimetoksifenyyli)-1-/2-(4-fluorifenyyli)etyyli/-4-piperidiinimetanolin valmistamiseksi
EP1574219A3 (fr) Procédé d'inhibition de la fibrose avec un agoniste de la somatostatine
GB0117095D0 (en) "Process for the preparation of pure citalopram"
FI891338L (fi) Parannus menetelmään 2',3'-dideoksi-2',3'-didehydronukleosidien valmistamiseksi
LV5765B4 (lv) (S)-(-)-1-propil-2',6'-pipekoloksilidida hidrohlorida monohidrats ta iegusanas metode un to satuross farmaceitisks preparats
IT8919737A0 (it) Impiego di 5' metiltioadenosina, s adenosilmetionina e dei loro sali per la preparazione di composizioni farmaceutiche atte a ridurre la seborrea e composizioni farmaceutiche relative.
FR2760639B1 (fr) Association therapeutique mineralo-vitaminique sous forme de preparation unitaire liquide buvable